Rafael holdings expands leadership team with three highly experienced global biopharmaceutical executives to build a fully integrated cancer metabolism therapeutics company

Newark, n.j., aug. 17, 2021 /prnewswire/ -- rafael holdings, inc., (nyse: rfl), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, today announced the appointment of three senior biopharmaceutical leaders to its executive management team: gus kodersha, chief technical operations officer; melissa lozner, chief compliance & ethics officer; and brandi robinson, chief corporate affairs officer.
RFL Ratings Summary
RFL Quant Ranking